Browse Careers
Browse Investors

Bard Announces Introduction of Fluent Constant Flow Pump in Europe

MURRAY HILL, N.J.--(BUSINESS WIRE)--June 23, 2003--C. R. Bard, Inc. (NYSE-BCR) today announced the introduction of the Fluent(TM) constant flow pump in Europe, for implantation in patients for the treatment of chronic pain. The product will be marketed by Bard Access Systems, Inc., its subsidiary located in Salt Lake City, Utah, pursuant to a license and other arrangements with Infumedics Inc. of East Walpole, Massachusetts.

Implanted infusion pumps are used to treat a variety of medical conditions, most notably in the area of chronic pain management for the continuous delivery of morphine to the spinal cord. Chronic pain afflicts over 100 million people worldwide and is comprised of both malignant and non-malignant disease patient populations.

Constant flow pumps are devices with a fixed flow rate and a life generally estimated at 15 years. Novel features of the Fluent pump include a polymer housing that reduces its size and weight and Bard's superior catheter technology.

Dr. Paolo Poli, director of pain therapy and palliative care, Santa Chiara Hospital, Pisa, Italy, and first in the world to place the pump, comments, "The Fluent constant flow pump's advanced design with the new, easy to use catheter lock connection, has streamlined this surgical procedure saving me time in the O.R. Additionally, its smooth ergonomic shape and light weight appeals to the needs of my patients."

William H. Longfield, chairman and chief executive officer, said, "The launch of the Fluent constant flow pump marks a significant milestone in our strategy to enter the growing area of pain management. We expect to follow this with the launch of a programmable device in 2004. This market represents an excellent growth opportunity for Bard and we are truly excited about our strategy to capitalize on it."

C. R. Bard, Inc., ( headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of health care products in the fields of vascular, urology, oncology and surgical specialty products.

This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our March 31, 2003, Form 10-Q for a statement with regard to forward-looking statements, including disclosure of additional factors that could cause actual results to differ materially from those expressed or implied.

    CONTACT: C. R. Bard, Inc.
             Investor Relations:
             Eric J. Shick, 908/277-8413
             Media Relations:
             Holly P. Glass, 703/754-2848

    SOURCE: C. R. Bard, Inc. 


Primary Media Relations Contact

Scott Lowry
Vice President and Treasurer
C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

Tel: 908-277-8365